Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
Phase 3positiveLunsumioPositive
AI Analysis
Summary
Roche's Lunsumio (bispecific T cell engager) achieved positive Phase 3 results in slow-growing lymphoma, clearing the path for full regulatory approval and label expansion.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Passed Phase 3 confirmatory trial in slow-growing lymphoma
Importance:8/10
Sentiment:
0.85
Phase 3 triallymphomalabel expansionbispecific antibodyT cell engagerregulatory approval pathway
Related Companies
Read the original article
Published by Endpoints News on September 17, 2026 2:34 PM